Back to Search Start Over

Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.

Authors :
Wang W
Wang X
Jiang Y
Guo Y
Fu P
He W
Fu X
Source :
British journal of cancer [Br J Cancer] 2025 Feb; Vol. 132 (2), pp. 203-211. Date of Electronic Publication: 2024 Nov 28.
Publication Year :
2025

Abstract

Background: Individuals with normal weight obesity (NWO) often escape the attention of healthcare providers who may assume that a normal body mass index (BMI) correlates with low health risks. However, it remains unknown whether NWO increases the risk of breast cancer.<br />Methods: This study included 22,257 and 52,506 pre- and postmenopausal females with normal BMI in the UK Biobank. NWO was defined as participants with a normal BMI (18.5-24.9 kg/m2) and an excess percent body fat (PBF > 33.3%). Cox proportional hazard models were used to investigate the associations of NWO and NWO-related biomarkers with incident breast cancer.<br />Results: NWO was not associated with premenopausal breast cancer, whereas it was associated with a higher risk of postmenopausal breast cancer (hazard ratio = 1.19, 95% CI: 1.08-1.31). In our meta-analysis, per 5-unit increment in percent body fat level was linked to a 15% (95% CI: 10-19%) elevated risk of postmenopausal breast cancer in females with normal BMI. Stratified analyses showed a stronger positive association in females with higher genetic risk. In our NWO-biomarkers analyses, NWO was linked to 34 identified biomarkers, of which three inflammation markers (monocyte count, neutrophil count, and C-reactive protein), and one ketone body metabolite (β-Hydroxybutyrate) also indicated a positive association with postmenopausal breast cancer.<br />Conclusions: NWO is associated with an increased risk of postmenopausal breast cancer, indicating that relying solely on BMI neglects the higher risk faced by non-obese postmenopausal women.<br />Competing Interests: Competing interests: The author declares no competing interests. Ethics approval and consent to participate: The UK Biobank was approved by the North West Multi centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. All participants provided their informed written consent before participation. This study was performed in accordance with the Declaration of Helsinki.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1532-1827
Volume :
132
Issue :
2
Database :
MEDLINE
Journal :
British journal of cancer
Publication Type :
Academic Journal
Accession number :
39609539
Full Text :
https://doi.org/10.1038/s41416-024-02906-1